Galena Biopharma (GALE) Tops Views

Galena Biopharma, Inc. (GALE) shares are up $0.12, or 6%, to $2.12 in after-hours trading Thursday after the company reported its fourth quarter 2014 earnings results.

The biopharmaceutical firm reported earnings of ($0.06) per share on revenues of $3.2 million, up 142.6% from a year ago. Analysts were expecting EPS of ($0.11) on revenues of $2.58 million.

For full-year 2014, the company reported net revenue of $9.3 million, compared $2.5 million for the same period of 2013.

On valuation measures, Galena Biopharma Inc. shares, which currently have an average 3-month trading volume of 1.57 million shares, trade with a price-to-sale ratio of 31.83. The median Wall Street price target on the name is $6.50 with a high target of $8.00. Currently ticker boasts 6 ‘Buy’ endorsements, compared to 1 ’Hold’ and 1 ‘Sell’.

Profitability-wise, GALE has a t-12 operating margin of (714.82%). The $242.91 million market cap company reported $23.7 million in cash vs. $43,429 in total liabilities in its most recent quarter.

GALE currently prints a one year loss of about 51% and a year-to-date return of around 29.15%.

The chart below shows where the equity has traded over the last 52 weeks.

Galena Biopharma, Inc., is a biopharmaceutical company focused on developing oncology treatments that address major unmet medical needs to advance cancer care. The company was founded in 2003 and is based in Lake Portland, Oregon.

Be the first to comment

Leave a Reply

Your email address will not be published.


*